Galera Therapeutics, Inc.
GRTXDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
GC4419 90mg
Oral Mucositis
GC4419
Pancreatic Cancer
Drug: GC4419
Head and Neck Cancer
Low Dose GC4419: 30mg/day
Radiation Induced Oral Mucositis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GC4419 90mg | Phase 3 | Oral Mucositis | - | - |
GC4419 | Phase 2 | Pancreatic Cancer | - | - |
Drug: GC4419 | Phase 2 | Head and Neck Cancer | - | - |
Low Dose GC4419: 30mg/day | Phase 2 | Radiation Induced Oral Mucositis | - | - |
Pancreatic Cancer
1 drug in this indication
Radiation Induced Oral Mucositis
1 drug in this indication
Oral Mucositis
1 drug in this indication
Head and Neck Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Galera Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Galera Therapeutics, Inc.'s (GRTX) pipeline across Phase 3, Phase 2. Its lead program is GC4419 90mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galera Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galera Therapeutics, Inc. (GRTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GRTX biotech catalysts?→
Add GRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galera Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.